COMMUNIQUÉS West-GlobeNewswire

Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc.
12/08/2025
$20 million drawn down at closing, with access to up to an additional $25 million Strengthens Company’s financial position and reinforces ability to achieve positive cash flow LEXINGTON, Mass., Aug. 12, 2025 (GLOBE [...]
Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results
12/08/2025
Reports second quarter 2025 total revenue of $7.3 million , representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024. [...]
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
12/08/2025
Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life Partnership with Seles will highlight the ‘Go for Greater’ [...]
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
12/08/2025
Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and marketable [...]
NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues
12/08/2025
Conference call will be held today, Tuesday, August 12 at 9:00 am ET CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company [...]
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
12/08/2025
Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease [...]
Altimmune Announces Second Quarter 2025 Financial Results and Business Update
12/08/2025
Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH [...]
Endure Biotherapeutics Receives SBIR Phase I Grant to Advance Engineered Native Bacteria Therapy for Familial Adenomatous Polyposis
12/08/2025
San Diego, Aug. 12, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Endure Biotherapeutics Receives SBIR Phase I Grant to Advance Engineered Native Bacteria Therapy for Familial Adenomatous Polyposis SAN DIEGO – August [...]
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights
12/08/2025
- ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And Done™ therapy for wet AMD - ARTEMIS enrollment completion expected in 1Q 2026 [...]
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR
12/08/2025
Ocular plans to outline clinical trial design, timing, and development strategy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME) at its Investor Day on September 30, 2025 BEDFORD, Mass [...]
SRx Health Solutions Initiates Restructuring Proceedings under CCAA for its Canadian Subsidiary
12/08/2025
U.S. operations, including Halo subsidiary, will not be affected by CCAA Proceedings; No U.S. bankruptcy filing expected TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) ( [...]
Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane’s and Happy Flower Brands
12/08/2025
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc . (“Tilray”) (NASDAQ: TLRY and TSX: TLRY) is building on the momentum of its hemp-derived Delta-9 THC (HDD9) beverage portfolio with new 10mg format [...]
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
12/08/2025
Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson’s Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated Analysis of functional changes and biomarker activity at [...]
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
12/08/2025
— Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple single ascending dose (SAD) [...]
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
12/08/2025
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Expect decision to advance an oligomer-targeted Enhanced [...]
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
12/08/2025
Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the Coming Weeks [...]
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
12/08/2025
MILAN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced that the U.S. Food [...]
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
12/08/2025
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as [...]
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
12/08/2025
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy [...]

Pages